STUDY OF JOINT SYNDROME AND CENTRAL HEMODYNAMIC DISORDERS IN THE COMORBID COURSE OF GOUT
Keywords:
gout, transventricular flow, left ventricular architecture, arterial hypertension, ischemic heart disease, comorbidityAbstract
Gout is not only an inflammatory disease of the joints, but also causes serious problems in the cardiovascular system. The specificity of the disease is associated with hyperuricemia, characterized by the accumulation of sodium urate crystals in various tissues and the inflammatory processes that develop in them. Studies show that patients with gout have a high risk of developing cardiovascular diseases, in particular, arterial hypertension, ischemic heart disease, heart failure and atherosclerosis. This risk is further increased by metabolic syndrome and an imbalance in the immune system. Identifying the relationship between gout and cardiovascular diseases and improving treatment methods is an urgent scientific issue.
References
Tairov D.R., Berdiev D.KH. "Gout: Immunological and genetic characteristics of the disease." Volume: 3, Issue: 12, Dec-2024. journals.academiczone.net.
Tairov D.R., Berdiev D.KH. "Characteristics of Cardiohemodynamic Disorders in Gout Disease." SCIENTIFIC PROGRESS. Volume 2, Issue 3, 2021. ISSN: 2181-1601.
Tairov D.R., Berdiev D.KH. "Medication and Non-Medication Methods to Eliminate Hyperuricemia in Gout." "Science and Education" Scientific Journal. Impact Factor 3.848. May 2023, Volume 4, Issue 5.
Tairov D.R., Berdiev D.KH. "Characteristics of Heart Functional Disorders in Gout Disease." GALAXY INTERNATIONAL INTERDISCIPLINARY RESEARCH JOURNAL (GIIRJ). ISSN (E): 2347-6915. Vol. 10, Issue 5, May 2022.
Tairov D.R., Berdiev D.KH. "Cardiovascular Damage and Metabolic Syndrome Comorbidities in Patients with Gout Disease." 2nd International Congress on Multidisciplinary Studies. Indonesia. February 20th, 2021. conferencepublication.com.
Nasonov E.L., Karateev D.E., Satibaldiyev A.M., et al. (2015).
Adams P.F. "Current Estimates from the National Health Interview Survey, 1996." Vital Health Stat. Vol. 10, 1999.
Saag K.G., Mikuls T.R. "Recent Advances in the Epidemiology of Gout." Curr. Rheumatol. Rep. Vol. 7, 2005, pp. 235–241.
Terkeltaub R.A. "Clinical Practice. Gout." N. Engl. J. Med. Vol. 349, 2003, pp. 1647–1655.
Tairov E.S., Tairov D.R. "Metabolic Syndrome in Gout: Its Relationship with Renal Functional Disorders." Questions of Science and Education. No. 28 (77), 2019.
Wallace K.L., Riedel A.A., Joseph-Ridge N. "Increasing Prevalence of Gout and Hyperuricemia Over 10 Years Among Older Adults in a Managed Care Population." J. Rheumatol. Vol. 31, 2004, pp. 1582–1587.
Tairov D.R., Makhmudova H.D. "Cardiovascular Damage in Patients with Gout." Scientific Progress. Vol. 2, No. 2, 2021, pp. 242–249.
Yarmukhamedova S.KH., Kamolova D.ZH. "Study of Myocardial Geometry in Hypertensive Patients Using Echocardiography." Achievements of Science and Education. No. 12 (53), 2019.
Eliseev M.S., Barskova V.G., Nasonov V.A. "Clinical Significance of Metabolic Syndrome in Gout." Clinical Gerontology. Vol. 12, No. 2, 2006, pp. 29–33.
Tairov E.S., Tairov D.R., Solovyev S.K. "Gout: Diagnosis and Treatment." Tashkent, Uzbekistan, 2020.
Sowers M.J., Whaley-Connell A., Hayden M.R. "The Role of Obesity in Cardiorenal Syndrome." Cardiorenal Medicine. Vol. 1, 2011, pp. 5–12.
Hayden M., Tyagi S.K. "Uric Acid: A New Perspective on an Old Cardiovascular Risk Marker." Nutr Metab (London). Vol. 1, 2004, p. 10.
Jalal D.I., Chonchol M., Chen W., Targher G. "Uric Acid as a Therapeutic Target in CKD." Am J. Dis., 2013, Vol. 61, pp. 134–146.
Johnson R.J., Segal M.S., Sautin Y., Nakagawa T., Feig D.I., Kang D.H., Gersch M.S., Benner S., Sanchez-Lozada L.G. "Potential Role of Sugar (Fructose) in the Epidemics of Hypertension, Obesity, and Metabolic Syndrome." Am J Clin Nutr. Vol. 86, 2007, pp. 899–906.
Steele T. "Human Urate Secretion: Pyrazinamide Suppression Test." Ann Intern Med. Vol. 79, 1973, pp. 734–737.
Suliman M.E., Johnson R.J., Garcia-Lopez E., et al. "J-Shaped Relationship Between Uric Acid and Mortality in CKD." Am J. Dis. Vol. 48, 2006, pp. 761–771.
Kan D.H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., Truong L., Harris R., Johnson R.J. "The Role of Uric Acid in Kidney Disease Progression." J Am Soc Nephrol. Vol. 13, 2002, pp. 2888–2897.
Tseng C. "Correlation of Urinary Albumin Excretion Rate with Uric Acid Levels in Type 2 Diabetes." Kidney Int. Vol. 68, 2005, pp. 796–801.
Ono I., Hosoya T., Gomi H., et al. "Serum Uric Acid and Kidney Failure Prognosis in IgA Nephropathy Patients." Nephron. Vol. 87, 2001, pp. 333–339.
Thomas G., Sehgal A.R., Kashyap S.R., Srinivas T.R., et al. "Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-Analysis." Clin J Am Soc Nephrol. Vol. 6, 2011, pp. 2364–2373.
Wright A.F., Rudan I., Hastie N.D., Campbell H. "The Complexity of Urate Transporters." Kidney Int. Vol. 78, 2010, pp. 446–452.
Gutman A.B., Yu T.F. "Urate Nephrolithiasis." Am J Med. Vol. 45, 1968, pp. 756–779.
